REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo aims to supercharge immune cells against Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests whether adding an experimental drug (NKTR-255) to standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has returned or not responded to treatment. About 27 participants will receive the combination to see if it i…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:54 UTC
-
New combo tackles tough lymphoma: early trial shows promise
Disease control OngoingThis early-phase study tests a combination of two drugs, ibrutinib and lenalidomide, in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The main goals are to find the safest dose and understand side effects. About 39 participan…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:54 UTC
-
Experimental cocktail targets aggressive blood cancer
Disease control OngoingThis early-phase study tests a combination of four drugs (atezolizumab, gemcitabine, oxaliplatin, and rituximab) in about 24 people with a type of lymphoma that has come back or stopped responding to prior treatments. The main goals are to find the safest dose and identify side e…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:53 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs—nivolumab and lenalidomide—in people with non-Hodgkin or Hodgkin lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs work together. About 36 adults with specific …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
New hope for lymphoma patients: targeted drug combo shows promise in late-stage trial
Disease control OngoingThis study tests whether adding a targeted drug (polatuzumab vedotin) to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to first treatment. About 306 adults will receive either the new combo or standard chemo alone. The m…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a new combination of drugs (PolaR-ICE) for people with diffuse large B-cell lymphoma that has come back or hasn't responded to initial treatment. The goal is to see if adding a targeted drug (polatuzumab vedotin) to standard chemotherapy can improve the chance of…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 05:42 UTC
-
Promising lymphoma combo trial pulled before it began
Disease control TerminatedThis study was designed to test whether combining three drugs—rituximab, venetoclax, and bortezomib—could shrink tumors in people with a fast-growing blood cancer called diffuse large B-cell lymphoma that had come back or stopped responding to standard therapy. The trial was with…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 26, 2026 05:41 UTC
-
New hope for tough blood cancers: early trial of Bcl-2 blocker begins
Disease control OngoingThis study tests a new drug called BGB-21447 for people with certain blood cancers (like lymphoma and leukemia) that have returned or not improved after prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors. About 112 participants will re…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 05:41 UTC
-
New drug duo offers hope for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of two drugs, copanlisib and venetoclax, in people with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 48 adults will take pa…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New cocktail targets tough lymphoma cancers
Disease control OngoingThis early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in 22 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see if the combination can shri…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Real-World data shows promise for epcoritamab in Tough-to-Treat lymphoma
Disease control OngoingThis study tracks how well the drug epcoritamab works for 150 adults with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. Researchers are measuring tumor shrinkage and side effects in everyday medical practice, not just in stric…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control OngoingThis early-stage trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogn…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tested a combination of two drugs—pembrolizumab (an immunotherapy) and vorinostat (a targeted therapy)—in 52 adults with certain types of lymphoma that had returned or stopped responding to standard treatments. The main goals were to find the safest dose of…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New cocktail shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tested a new combination of drugs (carfilzomib plus standard chemotherapy) in 29 adults with diffuse large B-cell lymphoma that returned or didn't respond to prior treatment. The goal was to find the best dose and see how well it shrinks tumors. The approach aims to im…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New hope for hard-to-treat lymphoma: targeted drug combo enters final testing phase
Disease control OngoingThis study tests a new drug combination (loncastuximab tesirine plus rituximab) against standard chemotherapy for adults with diffuse large B-cell lymphoma that has returned or not improved after at least one prior treatment. The goal is to see if the new combo can keep cancer fr…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Supercharged immune cells take on tough lymphoma after transplant
Disease control OngoingThis early-phase trial tests a new approach for people with aggressive B-cell non-Hodgkin lymphoma that has come back after treatment. After a standard stem cell transplant, patients receive their own immune cells (T cells) that have been genetically modified in a lab to better r…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC